BRPI0416993A - partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas - Google Patents

partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Info

Publication number
BRPI0416993A
BRPI0416993A BRPI0416993-0A BRPI0416993A BRPI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A BR PI0416993 A BRPI0416993 A BR PI0416993A
Authority
BR
Brazil
Prior art keywords
particle
diagnostic
agent
pharmaceutical
preparation process
Prior art date
Application number
BRPI0416993-0A
Other languages
English (en)
Inventor
Oskar Axelsson
Ib Leunbach
Magnus Karlsson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO20035294A external-priority patent/NO20035294D0/no
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Publication of BRPI0416993A publication Critical patent/BRPI0416993A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/10—Metallic powder containing lubricating or binding agents; Metallic powder containing organic material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F9/00—Making metallic powder or suspensions thereof
    • B22F9/16—Making metallic powder or suspensions thereof using chemical processes
    • B22F9/18—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds
    • B22F9/24—Making metallic powder or suspensions thereof using chemical processes with reduction of metal compounds starting from liquid metal compounds, e.g. solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

"PARTìCULA, PRODUTO FARMACêUTICO, AGENTE DE DIAGNóSTICO, AGENTE DE CONTRASTE DE RAIOS X, USO DE PARTìCULAS, MéTODOS DE DIAGNóSTICO, E DE FORMAçãO DE IMAGENS, E, PROCESSO PARA A PREPARAçãO DE PARTìCULAS". A invenção atual refere-se a núcleos dos compostos de particulas de tungstênio ou de tungstênio em mistura com outros elementos metálicos, como um material de melhoria de contraste onde o referido núcleo é revestido, a produtos farmacêuticos contendo as partículas, e ao uso de produtos farmacêuticos especificamente como agentes de contraste em imagens de diagnósticos, especialmente em imagens de raios X.
BRPI0416993-0A 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas BRPI0416993A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20035294A NO20035294D0 (no) 2003-11-28 2003-11-28 Forbindelser
NO20044622 2004-10-26
PCT/NO2004/000364 WO2005051435A2 (en) 2003-11-28 2004-11-26 Tungsten particles as x-ray contrast agents

Publications (1)

Publication Number Publication Date
BRPI0416993A true BRPI0416993A (pt) 2007-02-06

Family

ID=34635761

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416993-0A BRPI0416993A (pt) 2003-11-28 2004-11-26 partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas

Country Status (10)

Country Link
US (1) US20070031339A1 (pt)
EP (1) EP1694366A2 (pt)
JP (1) JP4974222B2 (pt)
KR (1) KR101128577B1 (pt)
AU (1) AU2004292917A1 (pt)
BR (1) BRPI0416993A (pt)
CA (1) CA2547476A1 (pt)
MX (1) MXPA06006044A (pt)
RU (1) RU2361617C2 (pt)
WO (1) WO2005051435A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20052428D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Kontrastmidler
NO20052429D0 (no) * 2005-05-20 2005-05-20 Amersham Health As Konstrastmidler
US8173166B2 (en) * 2005-09-09 2012-05-08 Honda Motor Co., Ltd. Methods of producing tungsten nanoparticles
US20070122620A1 (en) * 2005-11-02 2007-05-31 General Electric Company Nanoparticle-based imaging agents for x-ray / computed tomography and methods for making same
US9149545B2 (en) 2005-11-02 2015-10-06 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography and methods for making same
US7977568B2 (en) 2007-01-11 2011-07-12 General Electric Company Multilayered film-nanowire composite, bifacial, and tandem solar cells
US8003883B2 (en) 2007-01-11 2011-08-23 General Electric Company Nanowall solar cells and optoelectronic devices
JP5461547B2 (ja) 2008-07-07 2014-04-02 コーニンクレッカ フィリップス エヌ ヴェ Ｋ端イメージング
US8591783B2 (en) 2008-11-23 2013-11-26 Medtronic, Inc. Medical devices with encapsulated visibility particles
WO2013022499A2 (en) * 2011-04-22 2013-02-14 Emory University Polymer coated metal particles and uses related thereto
EP2753417A1 (en) * 2011-09-07 2014-07-16 Osmoblue SARL An apparatus and method for generating useful energy
US9989482B2 (en) * 2016-02-16 2018-06-05 General Electric Company Methods for radiographic and CT inspection of additively manufactured workpieces
US20200179539A1 (en) * 2016-06-22 2020-06-11 Board Of Regents, The University Of Texas System Contrast Agents and Methods of Making the Same for Spectral CT That Exhibit Cloaking and Auto-Segmentation
JP2019128288A (ja) * 2018-01-25 2019-08-01 三井化学株式会社 きずの観察方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181626A (en) * 1977-12-27 1980-01-01 Ppg Industries, Inc. Method of preparing tungsten hexacarbonyl containing polymers and polymers prepared thereby
US5314679A (en) * 1986-07-03 1994-05-24 Advanced Magnetics Inc. Vascular magnetic resonance imaging agent comprising nanoparticles
ATE132758T1 (de) * 1992-06-01 1996-01-15 Basf Ag Anwendung von dispersionen von magneto-ionischen partikeln in mri-kontrast-mitteln
US5728590A (en) * 1994-07-29 1998-03-17 Nanoprobes, Inc. Small organometallic probes
RU2147243C1 (ru) * 1994-09-27 2000-04-10 Нюкомед Имагинг А/С Контрастное средство
US5759230A (en) * 1995-11-30 1998-06-02 The United States Of America As Represented By The Secretary Of The Navy Nanostructured metallic powders and films via an alcoholic solvent process
JP3411497B2 (ja) 1998-03-25 2003-06-03 科学技術振興事業団 Ｗ超微粒子とその製造方法、およびｗナノ結晶薄膜
FR2777016B1 (fr) 1998-04-06 2002-06-14 Rhone Poulenc Agrochimie Silicone azotee utile pour compacter les sequences d'acides nucleiques et utilisation pour la transfection
JP4633258B2 (ja) * 1998-11-13 2011-02-16 バイオコンパテイブルズ・ユーケイ・リミテツド ポリマーの治療的使用
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
EP1259808A2 (en) 2000-03-10 2002-11-27 Washington University Method for labeling individual cells
CA2309575A1 (en) * 2000-05-26 2001-11-26 James E. Guillet Internally cross-linked macromolecules
ITVI20010126A1 (it) 2001-05-30 2002-11-30 Tecres Spa Cemento osseo radiopaco per uso ortopedico nonche' metodo di realizzazione
DE60219189T2 (de) 2001-07-20 2008-01-03 Iomed, Inc., Salt Lake City Iontophoretische okularvorrichtung zur abgabe von medikamenten auf methotrexat-basis und deren verwendung zur behandlung von neoplastischen, angiogenen, fibroplastischen und/oder immunsuppressiven augenunregelmässigkeiten
FR2830022B1 (fr) 2001-09-26 2004-08-27 Cime Bocuze Alliage base tungstene fritte a haute puissance
US6686308B2 (en) * 2001-12-03 2004-02-03 3M Innovative Properties Company Supported nanoparticle catalyst
WO2003075961A2 (en) * 2002-03-08 2003-09-18 James Hainfeld Gold nanoparticles used for x-rays imaging
US7462366B2 (en) 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) * 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization

Also Published As

Publication number Publication date
KR20060118515A (ko) 2006-11-23
WO2005051435A3 (en) 2006-07-13
JP4974222B2 (ja) 2012-07-11
MXPA06006044A (es) 2006-09-04
CA2547476A1 (en) 2005-06-09
RU2361617C2 (ru) 2009-07-20
AU2004292917A1 (en) 2005-06-09
JP2007512322A (ja) 2007-05-17
US20070031339A1 (en) 2007-02-08
RU2006117818A (ru) 2008-01-10
EP1694366A2 (en) 2006-08-30
WO2005051435A2 (en) 2005-06-09
KR101128577B1 (ko) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI0416993A (pt) partìcula, produto farmacêutico, agente de diagnóstico, agente de contraste de raios x, uso de partìculas, métodos de diagnóstico, e de formação de imagens, e, processo para a preparação de partìculas
Chakraborty et al. Zebrafish: A complete animal model to enumerate the nanoparticle toxicity
Moosmann et al. Designer benzodiazepines: a new challenge
Lasica et al. Review of venetoclax in CLL, AML and multiple myeloma
Gong et al. The role of reactive oxygen species in silicon dioxide nanoparticle-induced cytotoxicity and DNA damage in HaCaT cells
Golobič et al. Upon exposure to Cu nanoparticles, accumulation of copper in the isopod Porcellio scaber is due to the dissolved Cu ions inside the digestive tract
EA200601588A1 (ru) Стабилизированные перенасыщенные твёрдые растворы липофильных лекарственных средств
Bartoli et al. A short review on biomedical applications of nanostructured bismuth oxide and related nanomaterials
Kelley et al. Radioresistance of brain tumors
RU95113862A (ru) Производные пирролопиримидинов, фармацевтическая композиция, промежуточные соединения
BR0112903A (pt) Pó eletrostático
HUP0300059A3 (en) Quinazoline derivatives, process for their preparation, pharmaceutical compositions containing the compounds and use of the new and known quinazoline derivatives against proliferative disease
Karmarkar et al. Liquisolid tablets: a novel approach for drug delivery
Ali et al. Experimental and computational investigation on the molecular interactions of safranal with bovine serum albumin: Binding and anti-amyloidogenic efficacy of ligand
Huber et al. Protein affinity for TiO2 and CeO2 manufactured nanoparticles. From ultra-pure water to biological media
Eddy et al. Quantum and experimental investigation of the application of Crassostrea gasar (mangrove oyster) shell–based CaO nanoparticles as adsorbent and photocatalyst for the removal of procaine penicillin from aqueous solution
Obijole et al. Mechanochemically activated Aluminosilicate clay soils and their application for defluoridation and pathogen removal from groundwater
Matharu et al. Exploiting the antiviral potential of intermetallic nanoparticles
Ashour et al. Comparison and advanced antimicrobial strategies of silver and copper nanodrug-loaded glass ionomer cement against dental caries microbes
BR0115020A (pt) Suspensão de uma proteìna epi-hne, processo de preparação da mesma, aerossol de pó seco derivado da mesma, composições farmacêuticas contendo a suspensão referida ou o aerossol referido, e suas aplicações
Al-Sid-Cheikh et al. Synthesis and characterization of [110mAg]-nanoparticles with application to whole-body autoradiography of aquatic organisms
Chavata et al. Biofabrication of silver nanoparticles from aqueous leaf extract of Leucas aspera and their anticancer activity on human cervical cancer cells
Maher et al. Green Synthesis of Withania coagulans Extract-Mediated Zinc Oxide Nanoparticles as Photocatalysts and Biological Agents
Laskar et al. Acute radiation toxicity in head and neck and lung malignancies
Mallu et al. Hold time stability studies in pharmaceutical industry: Review

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.